CCR2 and pancreatic neoplasm: A phase Ib study (NCT02732938) evaluated the effect, safety and tolerability of CCR2 inhibitor PF-04136309 plus nab-paclitaxel and gemcitabine in aggressive pancreatic cancer (190).